Luis Féliz

ORCID

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 3

Top Venues

JCO precision oncology

Nature

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M Kas, Frank Rolfs, Catrin Lutz, Jessica K Lee, Sjoerd Klarenbeek, Ian M Silverman, Stefano Annunziato, Chang S Chan, Sander R Piersma, Timo Eijkman, Madelon Badoux, Ewa Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, Richard R de Goeij-de Haas, Gregory M Riedlinger, Hua Ke, Russell W Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, Linda Henneman, Martine H van Miltenburg, Natalie Proost, Huiling Zhen, Ellen Wientjens, Roebi de Bruijn, Julian R de Ruiter, Ute Boon, Renske de Korte-Grimmerink, Bastiaan van Gerwen, Luis Féliz, Ghassan K Abou-Alfa, Jeffrey S Ross, Marieke van de Ven, Sven Rottenberg, Edwin Cuppen, Anne Vaslin Chessex, Siraj M Ali, Timothy C Burn, Connie R Jimenez, Shridar Ganesan, Lodewyk F A Wessels, Jos Jonkers
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. Nature 608 (7923) (2022)
Kristen Bibeau, Luis Féliz, Christine F Lihou, Haobo Ren, Ghassan K Abou-Alfa
Progression-Free Survival in Patients With Cholangiocarcinoma With or Without FGF/FGFR Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response. JCO precision oncology 6 (2022)
Ian M Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert C Newton, Huiling Zhen, Luis Féliz, Camilla Zecchetto, Davide Melisi, Timothy C Burn
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib. Cancer discovery 11 (2) (2020)

Luis Féliz.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Luis Féliz